ERBB2 and breast cancer: Another study indicated that intertumoral delivery of DC combined with anti-HER2 therapy led to robust systemic antitumor immunity and complete regression in HER2-positive BC, as long as high levels of CD4+ and CD8+ T cells were present in the tumors [55].